In last trading session, Altamira Therapeutics Ltd (NASDAQ:CYTO) saw 80148.0 shares changing hands with its beta currently measuring 2.42. Company’s recent per share price level of $1.15 trading at -$0.07 or -5.78% at ring of the bell on the day assigns it a market valuation of $2.57M. That closing price of CYTO’s stock is at a discount of -1395.65% from its 52-week high price of $17.20 and is indicating a premium of 8.7% from its 52-week low price of $1.05. Taking a look at company’s average trading volume volume of 967.73K if we extend that period to 3-months.
Altamira Therapeutics Ltd (NASDAQ:CYTO) trade information
Upright in the red during last session for losing -5.78%, in the last five days CYTO remained trading in the green while hitting it’s week-highest on Tuesday, 07/02/24 when the stock touched $1.15 price level, adding 7.26% to its value on the day. Altamira Therapeutics Ltd’s shares saw a change of -66.97% in year-to-date performance and have moved 3.56% in past 5-day. Altamira Therapeutics Ltd (NASDAQ:CYTO) showed a performance of -22.33% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Altamira Therapeutics Ltd (CYTO) estimates and forecasts
Statistics highlight that Altamira Therapeutics Ltd is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -66.78% of value to its shares in past 6 months, showing an annual growth rate of 74.15% while that of industry is 13.90. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 50.52% during past 5 years.
CYTO Dividends
Altamira Therapeutics Ltd is more likely to be releasing its next quarterly report in August and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
